The indiference was worse than the virus itself
For decades, David France has chronicled how the AIDS crisis exposed the moral architecture of institutional neglect — how stigma, silence, and political indifference transformed a manageable epidemic into a global catastrophe. His work traces not only the virus but the human choices that allowed it to spread, and the extraordinary counter-movement of activists who forced medicine itself to change. Now, in 2026, France watches the conditions of that era reassemble: healthcare politicized, science distrusted, and the hard-won lessons of a generation at risk of dissolving into abstraction.
- Political inaction and moral stigma delayed the AIDS response by fifteen years, and France argues the same machinery of indifference is quietly rebuilding itself in the current climate of anti-science sentiment.
- AIDS activists didn't just march — they entered pharmaceutical boardrooms, reshaped clinical trial design, and forced an entire industry to see patients as people rather than market abstractions, a revolution whose legacy now spans every major disease.
- The COVID response moved faster because scientists who had fought AIDS brought hard-earned lessons with them, yet drug pricing repeated the same moral failure: vaccines arrived quickly for the wealthy and slowly for the world.
- A vaccine capable of eradicating HIV entirely remains undeveloped — not for lack of science, but for lack of political will — leaving the current generation to manage the virus as a chronic condition while shareholders profit.
- France himself could not speak publicly about AIDS until 2012, twenty years after losing his partner; the PTSD was severe, the grief intact, and his mission now is to prevent those lessons from becoming mere history.
David France has spent decades documenting what the AIDS crisis revealed about the machinery of indifference. The Oscar-nominated journalist and documentarian behind "How to Survive a Plague" has expanded his investigation into a book that traces not just the virus's spread but the deliberate choices — and refusals — that allowed it to become a global catastrophe.
France covered the early years of AIDS for a small LGBTQ+ publication while major outlets delayed their coverage for thousands of deaths. He argues that the conditions enabling that silence are reassembling themselves: healthcare in the United States has become explicitly politicized, and anti-science sentiment is growing globally. In 2024, he might have said such a slow, dehumanized response could not happen again. In 2026, he is no longer certain.
What distinguishes his account is the refusal to separate the medical from the moral. When AIDS was framed as divine punishment rather than viral transmission, the delay was not accidental. Language, France insists, is consequential — it can save lives or endanger them. Reagan took years to say the word AIDS publicly, and that silence cost millions.
Yet the book also documents something unexpected: how activism forced the machinery to change. AIDS activists entered pharmaceutical boardrooms and demanded participation in clinical trial design. They made scientists see 280 doses of a life-saving drug not as inventory but as 280 people who could be saved. Community advisory committees born from that struggle now exist across virtually every major pharmaceutical company worldwide.
The COVID pandemic benefited directly from this legacy — scientists who had fought AIDS brought ethical agility to the response. But the lesson on pricing was not learned. Vaccines arrived rapidly for wealthy nations and slowly for the rest of the world, economic benefit once again prevailing over human impact.
France speaks with urgency about what is being lost now. PrEP is publicly funded in many countries, and HIV is medically manageable — yet a vaccine that could eradicate the virus entirely remains undeveloped, a failure of political will rather than science. The virus persists as a chronic condition, profitable to investors, while the Trump administration has undermined global medication initiatives and clinics face the return of severe illness and stigma.
France lost his partner in 1992 and attended funerals weekly for years. He could not speak publicly about AIDS until 2012, when he wept onstage at his film's premiere, unable to answer questions. Fourteen years later, he says he is mostly recovered. His mission now is to keep speaking — to ensure that what was learned does not calcify into historical abstraction. The lesson, he tells public health students, is simple: no intervention succeeds without the community in its design.
David France has spent decades documenting what the AIDS crisis revealed about the machinery of indifference. The Oscar-nominated journalist and documentarian, whose 2012 film "How to Survive a Plague" examined the epidemic's human toll, has now expanded that investigation into a book that traces not just the virus's spread but the deliberate choices—and refusals—that allowed it to metastasize into a global catastrophe.
France's career has moved through the wreckage of institutional failure. He covered the early years of AIDS for a small LGBTQ+ publication called New York Native when major outlets like The New York Times delayed covering the epidemic for thousands of deaths. He has written about sexual abuse in the Catholic Church and directed documentaries on persecution in Chechnya. But AIDS remains his central preoccupation, the event that taught him how power operates in moments of crisis. When asked whether a similarly slow and dehumanized response could happen today, France pauses. In 2024, he might have said no. But it is now 2026, and the answer has changed. Healthcare in the United States has become explicitly politicized, he argues, and anti-science sentiment is growing globally. The conditions that allowed thousands to die in the 1980s—not from the virus alone, but from stigma, silence, and deliberate neglect—are reassembling themselves.
What distinguishes France's account is his refusal to separate the medical from the moral. When early cases were framed as "gay cancer" and attributed to divine punishment rather than viral transmission, the delay was not accidental. Government officials and scientists spoke of AIDS as retribution for moral transgression. This blindness, born of ignorance and hatred, he argues, was responsible for fifteen years of uncontrolled deaths worldwide and delayed the arrival of medications to the regions that needed them most. Ronald Reagan took years to speak the word AIDS publicly. Language, France insists, is not decoration—it is consequential. The way words are deployed can save lives or endanger them.
Yet the book also documents something unexpected: how activism forced the machinery to change. AIDS activists did not merely protest. They entered pharmaceutical boardrooms and demanded a seat at the table. They insisted on participation in clinical trial design, on community advisory committees, on the right to shape the very research meant to save them. What surprised France most while writing was discovering that pharmaceutical scientists had never imagined the human being who would take their medication. They thought in compounds and market share and stock prices. It took activists to make them see 280 doses of a life-saving drug not as inventory but as 280 people who could be saved. That shift—from abstraction to the concrete reality of individual lives—became revolutionary. Those community advisory committees now exist in virtually every major pharmaceutical company worldwide, for every disease.
The COVID pandemic, France argues, benefited directly from this legacy. Many of the scientists and public health officials who responded to COVID had fought AIDS in the early 1980s. They had learned, through their relationships with patients and activists, to approach science differently. They were prepared, agile, ethically conscious. The activism that emerged from AIDS fundamentally changed medicine and science. But the lesson about drug pricing was not learned. Vaccines were developed rapidly but priced beyond reach for most of the world. It took more than a year for them to become affordable elsewhere. Economic benefit prevailed over human impact, just as it had before.
France speaks with particular urgency about what is being lost now. HIV is medically manageable in many countries. PrEP—pre-exposure prophylaxis—is publicly funded in Spain and elsewhere. Young people can live without fear of infection. But what has not happened, and what France sees as a failure of political will, is the development of a vaccine that would eradicate the virus entirely. The current generation living with HIV would be the last to do so, if such a vaccine existed. Instead, the virus persists as a chronic condition, profitable to shareholders and investors. The Trump administration has sabotaged global initiatives to deliver medications to the Global South. Clinics now face the real possibility of severe illness and death returning. With it will come the stigma that activists have spent decades fighting to dismantle.
When France finally began writing about his own experience—his partner died in 1992, and he witnessed funerals weekly—he found the emotional weight almost unbearable. He made the documentary first, in 2008 and 2009, working with archival footage to remember what had been lived through. The grief was intact even as memory had faded. He could not speak publicly about AIDS until 2012. When the film premiered, he took the stage to answer questions and simply could not speak. He wept. The PTSD was severe. Fourteen years later, he says, he is mostly recovered. His mission now is to keep speaking, to ensure that what was learned does not calcify into historical abstraction. The lesson, he tells public health students, is simple: no intervention succeeds without the community in its design. Pandemics will come faster now. That principle must be applied again and again.
Notable Quotes
The scientists of pharmaceutical companies never imagined the human being who would take the medication. They thought in results, in new compounds, in market share or stock prices.— David France
If we could change medicine and science as people without scientific training, if we could do that as people with HIV, then we can face anything. That lesson we must know because we can apply it again and again.— David France
The Hearth Conversation Another angle on the story
You lost your partner in 1992. You've spent decades documenting this history. What made you finally ready to write the book?
I wasn't ready for a long time. I made the documentary first, in 2008 and 2009, working with old footage to remind myself what it had actually been like. The emotional weight was devastating. I couldn't speak publicly about any of it until 2012. When the film premiered, I literally could not speak on stage—I just wept. The trauma was that severe.
And now, fourteen years later, you can speak about it. What changed?
Time, partly. But also understanding that silence serves no one. The people who died deserve to be remembered not as historical figures but as people whose deaths were preventable. And the lessons from that time—about how to organize, how to force institutions to listen—those are urgent now.
You mention that pharmaceutical scientists never imagined the human being who would take their medication. That seems almost absurd.
It's not absurd—it's how the system was designed. They thought in compounds, in market share, in stock prices. It took activists literally saying, "If 280 people were on a plane heading toward a mountain, wouldn't you try to save them?" That concrete, human framing was revolutionary to them. They had to be forced to see the person.
Do you think that lesson stuck? Or are we repeating the same mistakes with drug pricing?
We're repeating them. COVID vaccines were developed rapidly, but they were priced out of reach for most of the world for over a year. Economic benefit won again. And now, with HIV, we have the capacity to develop an eradication vaccine, but there's no political will. The virus is more profitable as a chronic condition.
That's a damning statement. You're saying the system has learned nothing about prioritizing human life over profit.
Not nothing. The community advisory committees exist now. Patient voices matter in ways they didn't before. But the fundamental question—whose life matters, and at what price—that question is still being answered the same way it was in 1981.
What frightens you most right now?
The anti-science sentiment. The politicization of healthcare. In the 1980s, the indiference was involuntary—there was no cultural consensus about the humanity of LGBTQ+ people. Now, in 2026, that acceptance is being aggressively questioned. We could absolutely see another AIDS-like response. And that terrifies me.